Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3500-0.1800 (-5.10%)
At close: 04:00PM EDT
3.3800 +0.03 (+0.90%)
After hours: 04:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close3.5300
Open3.5500
Bid3.3300 x 900
Ask3.3600 x 900
Day's Range3.3250 - 3.7400
52 Week Range3.3250 - 18.4300
Volume719,272
Avg. Volume729,246
Market Cap237.193M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.9800
Earnings DateMay 10, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KZR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kezar Life Sciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/26/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Business Wire

    Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 14, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

  • Business Wire

    Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

    SOUTH SAN FRANCISCO, Calif., March 13, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.

  • Business Wire

    Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

    SOUTH SAN FRANCISCO, Calif., March 06, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

Advertisement
Advertisement